Niagen Bioscience, Inc.
NAGE
$4.78
-$0.04-0.83%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 129.42M | 124.71M | 116.30M | 107.93M | 99.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 129.42M | 124.71M | 116.30M | 107.93M | 99.60M |
| Cost of Revenue | 46.23M | 45.03M | 42.31M | 40.46M | 38.01M |
| Gross Profit | 83.19M | 79.68M | 73.99M | 67.46M | 61.59M |
| SG&A Expenses | 62.56M | 54.44M | 51.89M | 49.05M | 47.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 115.13M | 105.41M | 99.63M | 94.70M | 91.87M |
| Operating Income | 14.30M | 19.30M | 16.67M | 13.23M | 7.73M |
| Income Before Tax | 18.19M | 21.25M | 18.33M | 14.58M | 8.86M |
| Income Tax Expenses | 810.00K | 823.00K | 601.00K | 473.00K | 305.00K |
| Earnings from Continuing Operations | 17.38 | 20.43 | 17.73 | 14.11 | 8.55 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.38M | 20.43M | 17.73M | 14.11M | 8.55M |
| EBIT | 14.30M | 19.30M | 16.67M | 13.23M | 7.73M |
| EBITDA | 15.08M | 20.08M | 17.45M | 14.02M | 8.54M |
| EPS Basic | 0.22 | 0.26 | 0.23 | 0.18 | 0.11 |
| Normalized Basic EPS | 0.13 | 0.17 | 0.15 | 0.12 | 0.07 |
| EPS Diluted | 0.20 | 0.24 | 0.21 | 0.17 | 0.10 |
| Normalized Diluted EPS | 0.12 | 0.16 | 0.14 | 0.11 | 0.07 |
| Average Basic Shares Outstanding | 316.69M | 313.78M | 309.98M | 306.29M | 303.71M |
| Average Diluted Shares Outstanding | 341.38M | 337.77M | 328.92M | 318.24M | 310.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |